

RESEARCH

Open Access



Fusion of the *HMGA2* and *C9orf92* genes in myolipoma with t(9;12)(p22;q14)

Ioannis Panagopoulos^{1,2*}, Ludmila Gorunova^{1,2}, Antonio Agostini^{1,2}, Ingvild Lobmaier³, Bodil Bjerkehagen³ and Sverre Heim^{1,2,4}

Abstract

Background: Myolipoma of soft tissue is an extremely rare benign tumor composed of mature adipose tissue and smooth muscle cells. It is found predominantly in women. The cytogenetic and molecular genetic features of myolipomas remain largely unexplored. Here we present the first cytogenetically analyzed myolipoma.

Methods: Cytogenetic and molecular genetic analyses were done on a myolipoma.

Results: G-banding analysis of short-term cultured cells from the myolipoma yielded a karyotype with a single clonal chromosome abnormality: 46,XX,t(9;12)(p22;q14). Fluorescence in situ hybridization experiments demonstrated that *HMGA2* (in 12q14) was rearranged. Molecular genetic analysis showed that the translocation resulted in fusion of *HMGA2* with the *C9orf92* gene (from 9p22). The *HMGA2-C9orf92* fusion transcript would code for a putative protein containing amino acid residues 1–94 of *HMGA2* and 6 amino acid residues from the out-of-frame fusion with exon 4 of *C9orf92*.

Conclusion: The pattern of *HMGA2* rearrangement in the present case of myolipoma is similar to what is found in other benign connective tissue tumor types, including lipomas, i.e., disruption of the *HMGA2* locus leaves intact exons which encode the AT-hook domains but separates them from the 3'-terminal part of the gene. Whether any genetic features differentiate myolipomas from regular lipomas with *HMGA2*-involvement is a question that cannot be answered until more cases of the former tumor type are subjected to genetic analysis.

Keywords: Myolipoma, Chromosome translocation, Fusion gene, *HMGA2*, *C9orf92*

Background

Myolipoma of soft tissue is a benign tumor composed of mature adipose tissue and smooth muscle [1]. It was first described as an entity in 1991 by Meis and Enzinger (as myolipoma of soft tissue) [2] and Scurry et al. (as soft tissue lipoleiomyoma) [3]. The tumor is extremely rare and is found predominantly in women. Searching PubMed (<http://www.ncbi.nlm.nih.gov/pubmed/>) using the term “myolipoma” we found that around 50 cases have been reported since 1991 (Additional file 1: Table S1; data updated October 20, 2015). These tumors were found in 35 females and 14 males. The median age was 48 years

(range, 4–83) (Additional file 1: Table S1). Most publications have described single cases, further testifying to the rarity of the disease. The tumor is usually found as a deep-seated mass within the abdominal cavity, retroperitoneum, or inguinal region [2, 4–8], although other locations have been reported such as the tongue base, mesentery, pericardium, and eyelid (Additional file 1: Table S1). No cases with focal recurrence, metastatic disease or other signs of malignant transformation have been reported and cure is achieved by surgical resection [1].

The cytogenetic and molecular genetic features of myolipomas remain largely unexplored. In the 2013 edition of “WHO classification of tumours of soft tissue and bone”, the only genetic information on these tumors is that expression of full-length *HMGA2* was detected by RT-PCR in myolipoma of the pelvic cavity [1, 9].

* Correspondence: ioannis.panagopoulos@rr-research.no

¹Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953, Nydalen, NO-0424 Oslo, Norway

²Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway

Full list of author information is available at the end of the article



Here we present the first cytogenetically analyzed myolipoma. The tumor had a $t(9;12)(p22;q14)$ as the sole karyotypic aberration resulting in fusion of *HMG2* with the *C9orf92* gene.

Methods

Ethical approval

The study was approved by the Regional Committee for Medical and Health Research Ethics, South-East Norway (REK Sør) <http://helseforskning.etikkom.no>). Written informed consent was obtained from the patient. The consent included acceptance that his clinical details be published. The ethics committee's approval included a review of the consent procedure. All patient information has been anonymized.

Patient

The patient is a 66 years old female who underwent an abdominal CT-scan due to pain radiating into the left lower extremity. The scan revealed a well demarcated, lipogenic tumor in the left retroperitoneum measuring

almost 20 cm in greatest diameter, invoking a suspicion of liposarcoma. The tumor was completely excised. The operation specimen showed a lipomatous tumor which was macroscopically well demarcated and without infiltrative growth. Microscopic evaluation showed a lipomatous tumor with areas with smooth muscle differentiation, without signs of malignancy (Fig. 1a and b). There were no suspect lipoblasts. Smooth muscle fibers showed positive reaction for desmin (Fig. 1c) and smooth muscle actin (SMA) (Fig. 1d) by immunohistochemical examination. MDM2 immunostaining was negative (Fig. 1e).

Chromosome banding analysis and Fluorescence in situ hybridization (FISH)

Fresh tissue from a representative area of the tumor was received and cells from it were short-term cultured and analyzed cytogenetically as part of our diagnostic routine as described elsewhere [10]. The karyotype was written according to the International System for Human Cytogenetic Nomenclature (ISCN) 2013 guidelines [11].




Fig. 1 Microscopic image of the myolipoma. **a** and **b** H&E stained slides 10X (**a**) and 20X (**b**) magnification with mature fat between bundles of spindle cells, confirmed as smooth muscle fibers by immunohistochemical examination showing positive reaction for desmin (**c**) and smooth muscle actin (SMA) (**d**). MDM2 immunostaining was negative (**e**)

FISH analysis based on the karyotyping findings (see below) was performed on metaphase plates as described previously [10]. BAC clones were retrieved from the Human genome high-resolution BAC re-arrayed clone set (the “32k set”; BACPAC Resources, <http://bacpac.chori.org/pHumanMinSet.htm>). The “32k set” is mapped on the UCSC Genome browser on Human May 2004 (NCBI/hg17) assembly. Mapping data for the 32k human re-array are available in an interactive web format (<http://bacpac.chori.org/pHumanMinSet.htm>, from the genomic rearrays page) and are obtained by activation of the ucsc browser track for the hg17 UCSC assembly from the “32k set” homepage (<http://bacpac.chori.org/genomicRearrays.php>). The BAC clones were selected according to physical and genetic mapping data on chromosome 12 as reported on the Human Genome Browser at the University of California, Santa Cruz website (May 2004, <http://genome.ucsc.edu/>). In addition, FISH mapping of the clones on normal controls was performed to confirm their chromosomal location. The clones used were RP11-185 K16, (chr12:64103524–64274514), RP11-30I11 (chr12:64178505–64349708), RP11-662G15 (chr12:64288763–64498219), RP118B13 (chr12:64644968–64789255), RP11-745O10 (chr12:64752327–64926193), and RP11-263A04 (chr12:64908453–65103538). All of them map to chromosome subband 12q14.3 (Fig. 2a). DNA was extracted, and probes were labelled with Fluorescein-12-dCTP (PerkinElmer, Boston, MA, USA) and Texas Red-5-dCTP (PerkinElmer) in order to obtain green and red signals, respectively, using the Abott’s nick translation kit (Des Plaines, IL, USA), and hybridized according to Abbott Molecular recommendations (<http://www.abbott-molecular.com/home.html>). A homemade breakapart *HMGA2* probe was used. The 5′-end of the probe (red signal) was constructed from a pool of the clones RP11-185K16, RP11-30I11, and RP11-662G15. The 3′-end of the probe (green signal) was constructed from a pool of the clones RP118B13, RP11-745O10, and RP11-263A04. All of them map to chromosome subband 12q14.3 and cover the *HMGA2* locus (Fig. 2a).

Molecular analyses

Tumor tissue adjacent to that used for cytogenetic analysis and histologic examination had been frozen and stored at -80°C . Total RNA was extracted using miRNeasy Mini Kit according to the manufacturer’s instructions (Qiagen Nordic, Oslo, Norway). Tumor tissue was disrupted and homogenized in Qiazol Lysis Reagent (Qiagen) using 5 mm stainless steel beads and TissueLyser II (Qiagen). Subsequently, total RNA was purified using QIAcube (Qiagen). Human Universal Reference Total RNA was used as control (Clontech Laboratories, TaKaRa-Bio Group, Europe/SAS, Saint-Germain-en-Laye, France). According to the company’s information, it is a mixture of

total RNAs from a collection of adult human tissues chosen to represent a broad range of expressed genes. Both male and female donors are represented.

The 3′-RACE methodology was described in detail elsewhere [10]. To verify the results obtained by 3′-RACE, i.e., the presence of an *HMGA2-C9orf92* chimeric transcript (see below), RT-PCR was performed using the forward *HMGA2*-936F1 (5′-AGC CCT CTC CTA AGA GAC CCA G-3′) and the reverse *C9orf92*-316R1 (5′-TGA AGT TTT AAT CAA CAC AAG CAG C-3′) primers. Total RNA (1 μg) was reverse-transcribed in a 20 μL reaction volume using iScript Advanced cDNA Synthesis Kit for RT-qPCR according to the manufacturer’s instructions (Bio-Rad Laboratories, Oslo, Norway). The 25 μL PCR volume contained 12.5 μL Premix Ex Taq DNA Polymerase Hot Start Version (Takara Bio), 1 μL of cDNA, and 0.4 μM of each of the forward *HMGA2*-936F1 and reverse *C9orf92*-316R1 primers. PCR amplifications were run on a C-1000 Thermal cycler (Bio-Rad Laboratories) with an initial denaturation at 94°C for 30 s, followed by 35 cycles of 7 s at 98°C , 30 s at 58°C , 1 min at 72°C , and a final extension for 5 min at 72°C . Three μL of the PCR products were stained with GelRed (Biotium, Hayward, CA, USA), analyzed by electrophoresis through 1.0 % agarose gel, and photographed. The remaining 22 μL PCR products were purified using the MinElute PCR purification kit (Qiagen) and sequenced at GATC Biotech (Germany, <http://www.gatc-biotech.com/en/home.html>). The BLAST software (<http://blast.ncbi.nlm.nih.gov/Blast.cgi>) was used for computer analysis of sequence data.

Results

G-banding analysis

G-banding analysis of short-term cultured cells from the myolipoma yielded a karyotype with a single clonal chromosome abnormality: 46,XX,t(9;12)(p22;q14) [12] (Fig. 2b).

FISH experiments showed that the *HMGA2* probe was split with one signal on der(12) and the other on der(9) (Fig. 2c).

Molecular genetic analysis

3′-RACE analysis amplified a single fragment (Fig. 2d). Subsequent Sanger sequencing showed that it was a chimeric cDNA fragment in which exon 4 of *HMGA2* from 12q14 (nt 1093 in the reference sequence with accession number NM_003483.4) was fused to exon 4 of the *C9orf92* gene from 9p22 (nt 261 in the reference sequence NM_001271829.1).

PCR with the primers *HMGA2*-936F1 and *C9orf92*-316R1 amplified a cDNA fragment from myolipoma but not from control (Fig. 2d). Direct sequencing of the PCR product showed the same fusion breakpoint as that detected in the 3′-RACE amplified fragment (Fig. 2e).




Fig. 2 Cytogenetic, FISH, and RT-PCR analyses of the myolipoma. **a**) Chromosome 12 ideogram showing the location of the *HMGGA2* locus and the BACs used for FISH experiments. The investigated region is indicated as a red box. **b**) Partial karyotype showing the der(9)t(9;12)(p22;q14) and der(12)t(9;12)(p22;q14) together with the corresponding normal chromosome homologs; breakpoint positions are indicated by arrows. **c**) FISH analysis with an *HMGGA2* breakpart probe. The green signal (pool of the BACs RP1118B13, RP11-745O10, and RP11-263A04) is moved to der(9) whereas the red signal (pool of the BACs RP11-185K16, RP11-30I11, and RP11-662G15) is seen on der(12). **d**) Amplification of an *HMGGA2-C9orf92* cDNA fragment using primers *HMGGA2*-936F1 and *C9orf92*-316R1 in myolipoma (T) but not in control (C). M, 1 Kb DNA ladder (GeneRuler, Fermentas), Bl, Blank, water in cDNA synthesis. **e**) Partial sequence chromatogram of the cDNA fragment showing the fusion of *HMGGA2* with *C9orf92*

Discussion

We describe the first cytogenetic and molecular genetic analysis of a myolipoma. The tumor had an acquired chromosomal translocation, t(9;12)(p22;q14), which resulted in fusion of the *C9orf92* (from 9p22) and *HMGGA2* (from 12q14) genes. The *HMGGA2-C9orf92* fusion transcript codes for a putative protein which contains amino acid residues 1–94 of *HMGGA2* protein (accession number NP_003474.1), corresponding to exons 1–4 of the gene, and 6 amino acid residues (AHKEDT) coming from an out-of-frame fusion with exon 4 of *C9orf92*.

Information on *C9orf92* is very scant and nothing is known about its cellular localization or function (<http://www.ncbi.nlm.nih.gov/gene/100129385>). Two transcript variants have been reported: Transcript variant 1 (reference

sequence NM_001271829) which represents the shorter transcript and encodes a functional protein, and transcript variant 2 (reference sequence NR_073471) which uses an alternative 5' exon structure compared to variant 1. Transcript variant 2 is a non-coding RNA due to the presence of an upstream open reading frame (ORF) that is predicted to interfere with translation of the longest ORF (<http://www.ncbi.nlm.nih.gov/gene/100129385>). *C9orf92* is low expressed in many normal human tissues as shown by RNA-sequencing (<http://www.genecards.org/cgi-bin/carddisp.pl?gene=C9orf92&keywords=c9orf92>).

The translocation t(9;12)(p22;q14~15), or variants thereof, was reported before in lipomas [12–15], uterine leiomyomas [16, 17], chondroid hamartomas [18], and pleomorphic adenomas [19]. In lipomas and pleomorphic

adenomas, a cytogenetically similar recombination between 9p and 12q was shown to result in the fusion of *HMGA2* with *NFIB* [12, 13, 15, 19] which maps 2.2 Mbp distal to *C9orf92*.

In lipomas, two different *HMGA2-NFIB* fusion transcripts have been identified. In the first type, exons 1–4 of *HMGA2* were fused to exon 9 of *NFIB* [12, 13, 15]. In the second type, the fusion transcript consisted of the first three exons of *HMGA2*, exon 6 of *MSRB3* (12q14.3), and exon 9 of *NFIB* [15]. In both transcript types, a stop codon is present on the 3' side shortly after the fusion point of *HMGA2* with *NFIB* or *MSRB3* [12, 13, 15]. Similarly, the *HMGA2-NFIB* fusions found in pleomorphic adenomas also contain a stop codon located near but downstream of the fusion point [19].

The *NFIB* gene codes for a transcription factor which recognizes and binds the palindromic sequence 5-TTGGCNNNNNGCCAA-3 of viral and cellular promoters (<http://www.genecards.org/cgi-bin/carddisp.pl?gene=NFIB&keywords=NFIB>). No functional information is at hand about the *C9orf92* gene (<http://www.genecards.org/cgi-bin/carddisp.pl?gene=C9orf92&keywords=c9orf92>).

Although the t(9;12)(p22;q14~15) thus appears to be heterogeneous at the molecular level, generating *HMGA2-NFIB* in pleomorphic adenoma and lipomas but *HMGA2-C9orf92* in the only myolipoma examined, the pathogenetic pattern behind these changes is similar to that of *HMGA2* rearrangements found generally in benign connective tissue tumors, i.e., disruption of the *HMGA2* locus leaving intact exons 1–3 which encode the AT-hook domains and separates them from the 3'-untranslated region of the gene (3'-UTR) [20]. The 3'-UTR of *HMGA2* was shown to regulate the transcription of the *HMGA2* gene [21, 22].

Conclusion

The present case of myolipoma underscores the frequent and general role of *HMGA2* rearrangements in the genesis of several benign connective tissue tumors. Further studies are necessary to find out whether myolipomas of soft tissue in any systematic way differ from the other tumor types in the exact manner in which *HMGA2* is abrogated, in particular whether fusion with *C9orf92* is a general feature of these rare neoplasms.

Additional file

Additional file 1: Table S1. Cases of myolipomas which have been reported from 1991 until October 20, 2015. They were found searching pubmed (<http://www.ncbi.nlm.nih.gov/pubmed/>) using the term "myolipoma". (XLSX 17 kb)

Abbreviations

CT: Computed tomography; FISH: Fluorescence in situ hybridization; ORF: Open reading frame; PCR: Polymerase chain reaction; RACE: Rapid amplification of cDNA ends; UTR: Untranslated region; WHO: World Health Organization.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

IP designed the research, performed the molecular genetic analyses, interpreted the data, and wrote the manuscript. LG performed the cytogenetics and FISH experiments and interpreted the data. AA performed the molecular genetic analyses and interpreted the data. IL and BB did the pathologic evaluations. SH supervised the project, designed the research, evaluated the cytogenetics and FISH data, and wrote the manuscript. All authors read and approved the final version on the manuscript.

Acknowledgments

The authors wish to thank Hege Kilen Andersen for technical assistance. This work was supported by grants from the Norwegian Radium Hospital Foundation.

Author details

¹Section for Cancer Cytogenetics, Institute for Cancer Genetics and Informatics, The Norwegian Radium Hospital, Oslo University Hospital, P.O. Box 4953, Nydalen, NO-0424 Oslo, Norway. ²Centre for Cancer Biomedicine, Faculty of Medicine, University of Oslo, Oslo, Norway. ³Department of Pathology, The Norwegian Radium Hospital, Oslo University Hospital, Oslo, Norway. ⁴Faculty of Medicine, University of Oslo, Oslo, Norway.

Received: 28 November 2015 Accepted: 28 January 2016

Published online: 09 February 2016

References

- Meis JM, Kindblom L-G. Myolipoma of soft tissue. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, editors. World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Soft Tissue and Bone. Lyon: IARC Press; 2013. p. 27.
- Meis JM, Enzinger FM. Myolipoma of soft tissue. *Am J Surg Pathol*. 1991;15(2):121–5.
- Scurry JP, Carey MP, Targett CS, Dowling JP. Soft tissue lipoleiomyoma. *Pathology*. 1991;23(4):360–2.
- Michal M. Retroperitoneal myolipoma. A tumour mimicking retroperitoneal angiomyolipoma and liposarcoma with myosarcomatous differentiation. *Histopathology*. 1994;25(1):86–8.
- Liang EY, Cooper JE, Lam WW, Chung SC, Allen PW, Metreweli C. Case report: myolipoma or liposarcoma—a mistaken identity in the retroperitoneum. *Clin Radiol*. 1996;51(4):295–7.
- Oh MH, Cho IC, Kang YI, Kim CY, Kim DS, Cho HD, et al. A case of retroperitoneal lipoleiomyoma. *J Korean Med Sci*. 2001;16(2):250–2.
- Takahashi Y, Imamura T, Irie H, Tanaka F, Fukushima J, Fukusato T, et al. Myolipoma of the retroperitoneum. *Pathol Int*. 2004;54(6):460–3. doi:10.1111/j.1440-1827.2004.01646.x.
- Behranwala KA, Chettiar K, El-Bahrawy M, Stamp G, Kakkar AK. Retroperitoneal myolipoma. *World J Surg Oncol*. 2005;3:72. doi:10.1186/1477-7819-3-72.
- Hisaoka M, Sheng WQ, Tanaka A, Hashimoto H. HMGIC alterations in smooth muscle tumors of soft tissues and other sites. *Cancer Genet Cytogenet*. 2002;138(1):50–5.
- Panagopoulos I, Bjerkehagen B, Gorunova L, Taksdal I, Heim S. Rearrangement of chromosome bands 12q14 ~ 15 causing *HMGA2-SOX5* gene fusion and *HMGA2* expression in extraskeletal osteochondroma. *Oncol Rep*. 2015;34(2):577–84. doi:10.3892/or.2015.4035.
- Schaffer LG, McGowan-Jordan J, Schmid M. ISCN 2013: An International System for Human Cytogenetic Nomenclature Basel: Karger. 2013.
- Pierron A, Fernandez C, Saada E, Keslair F, Hery G, Zattara H, et al. *HMGA2-NFIB* fusion in a pediatric intramuscular lipoma: a novel case of *NFIB* alteration in a large deep-seated adipocytic tumor. *Cancer Genet Cytogenet*. 2009;195(1):66–70. doi:10.1016/j.cancergencyto.2009.06.009.
- Nilsson M, Panagopoulos I, Mertens F, Mandahl N. Fusion of the *HMGA2* and *NFIB* genes in lipoma. *Virchows Arch*. 2005;447(5):855–8. doi:10.1007/s00428-005-0037-9.
- Bartuma H, Hallor KH, Panagopoulos I, Collin A, Rydholm A, Gustafson P, et al. Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. *Genes Chromosomes Cancer*. 2007;46(6):594–606. doi:10.1002/gcc.20445.

15. Italiano A, Ebran N, Attias R, Chevallier A, Monticelli I, Mainguene C, et al. NFIB rearrangement in superficial, retroperitoneal, and colonic lipomas with aberrations involving chromosome band 9p22. *Genes Chromosomes Cancer*. 2008;47(11):971–7. doi:10.1002/gcc.20602.
16. Kiechle-Schwarz M, Sreekantaiah C, Berger CS, Pedron S, Medchill MT, Surti U, et al. Nonrandom cytogenetic changes in leiomyomas of the female genitourinary tract. A report of 35 cases. *Cancer Genet Cytogenet*. 1991;53(1):125–36.
17. Kataoka S, Yamada H, Hoshi N, Kudo M, Hareyama H, Sakuragi N, et al. Cytogenetic analysis of uterine leiomyoma: the size, histopathology and GnRH α -response in relation to chromosome karyotype. *Eur J Obstet Gynecol Reprod Biol*. 2003;110(1):58–62.
18. Kazmierczak B, Meyer-Bolte K, Tran KH, Wockel W, Brichtman I, Rosigkeit J, et al. A high frequency of tumors with rearrangements of genes of the HMGI(Y) family in a series of 191 pulmonary chondroid hamartomas. *Genes Chromosomes Cancer*. 1999;26(2):125–33.
19. Geurts JM, Schoenmakers EF, Roijer E, Astrom AK, Stenman G, van de Ven WJ. Identification of NFIB as recurrent translocation partner gene of HMGI(Y) in pleomorphic adenomas. *Oncogene*. 1998;16(7):865–72. doi:10.1038/sj.onc.1201609.
20. Cleyne I, Van de Ven WJ. The HMGA proteins: a myriad of functions (Review). *Int J Oncol*. 2008;32(2):289–305.
21. Borrmann L, Wilkening S, Bullerdiek J. The expression of HMGA genes is regulated by their 3'UTR. *Oncogene*. 2001;20(33):4537–41. doi:10.1038/sj.onc.1204577.
22. Kristjansdottir K, Fogarty EA, Grimson A. Systematic analysis of the Hmga2 3' UTR identifies many independent regulatory sequences and a novel interaction between distal sites. *RNA*. 2015;21(7):1346–60. doi:10.1261/na.051177.115.

Submit your next manuscript to BioMed Central and we will help you at every step:

- We accept pre-submission inquiries
- Our selector tool helps you to find the most relevant journal
- We provide round the clock customer support
- Convenient online submission
- Thorough peer review
- Inclusion in PubMed and all major indexing services
- Maximum visibility for your research

Submit your manuscript at
www.biomedcentral.com/submit

